Introduction {#sec1}
============

With the rapid advancement of human genetic research, researchers have found many genetic variations that contribute to disease susceptibility and drug responses.[@bib1], [@bib2], [@bib3] Based on these achievements, personalized medicine is expected to provide optimal medical treatment by taking into account individual genetic makeup.[@bib4], [@bib5]

To better achieve this goal, the Japanese Ministry of Education, Culture, Sports, Science and Technology launched the BioBank Japan (BBJ) Project in 2003. This project is being conducted in three 5-year periods. In the first period (April 2003 to March 2008), the project constructed a large, patient-based biobank, referred to as the BBJ, as the basic infrastructure for genetic research for common diseases; this was accomplished through the collection of clinical information and biological samples related to 47 target diseases and with the cooperation of 12 Japanese medical institutes. In the second period (April 2008 to March 2013), the project conducted various genomic investigations and identified genetic variations related to disease susceptibility and drug responses using a genome-wide association study approach.[@bib6] In the third period (April 2013 to March 2018), the project will expand the BBJ by enrolling new participants with 38 target diseases, starting sequence-based genomic analyses, and constructing a tissue bank.

Ultimately, the BBJ aims to (1) discover the genes that contribute to various diseases and those related to the efficacy or adverse reactions of drugs, (2) to provide useful information regarding molecular targets for the evidence-based development of new drugs and/or diagnostic tools, (3) to examine interactions between genetic and treatment factors related to the progression of diseases, and (4) to provide important medical information that can be applied to the implementation of personalized medicine.[@bib7] This project is jointly managed by The Institute of Medicine of The University of Tokyo and the RIKEN Center for Integrative Medical Sciences.

This paper provides an overview of the BBJ Project as well as a profile of the BBJ participants who were registered in the first 5-year period of the project.

Methods {#sec2}
=======

Study participants {#sec2.1}
------------------

The BBJ is a multi-institutional hospital-based registry that was initially designed to focus on the use of human genetic research. Therefore, this project registered not only patients with newly developed diseases (incident cases) but also patients who were diagnosed and treated before starting the project (prevalent cases). Project participants were recruited between June 2003 and March 2008 from 66 hospitals, which consisted of 12 cooperating medical institutions located throughout Japan ([Fig. 1](#fig1){ref-type="fig"}). Attending physicians identified patients with any of 47 target diseases. Before enrollment, patients received a detailed explanation regarding the project from expert, independent medical coordinators who were specifically trained for this project. Biological samples and clinical information were collected and anonymized on-site at the cooperating hospitals. All study participants had been diagnosed with one or more of 47 target diseases, which are listed in [Table 2](#tbl2){ref-type="table"}. These target diseases were selected by clinical importance based on morbidity or mortality in Japan through discussion with cooperating medical institutions. Diagnoses of these diseases were based on the physicians\' diagnoses at cooperating hospitals. We excluded patients who had received a bone marrow transplant and those who were not of East Asian descent.

Biobanking of biological samples and clinical information {#sec2.2}
---------------------------------------------------------

The study flow related to the collection of biological samples and clinical information is shown in [Fig. 2](#fig2){ref-type="fig"}. For biological samples, we collected DNA and serum samples from participants at the cooperating hospitals and stored them at the BBJ DNA bank and serum bank, respectively. Details of the blood sampling and storage processes are described in the Blood Sampling and Storage section. Clinical information was initially stored in the local server at the cooperating hospitals and was subsequently sent to the BBJ at the end of every year after anonymization.

Samples stored in the BBJ were provided to research institutions and companies beginning in 2005 after receiving approval from the Sample Providing Committee of this project. Detailed information about the distribution of the samples is available at the project website (<https://biobankjp.org/index.html>; Japanese only).[@bib8]

Baseline survey {#sec2.3}
---------------

We collected baseline clinical information through interviews and reviews of medical records using a standardized questionnaire ([Table 1](#tbl1){ref-type="table"}); full details of the questionnaire are available at the project website (<https://biobankjp.org/sample/pdf/list7.1.4.pdf>; Japanese only). The common items addressed during each interview included smoking and alcohol habits, height, weight, systolic and diastolic blood pressure, past history and family history of various diseases, frequency of food intake and physical exercise, and reproductive history (for female participants). The common items collected from medical record reviews included information about birth year, sex, drug use within one month before study entry, history of adverse drug events, and routine laboratory examination data (including complete blood count, urinalysis, and biochemical tests such as measurements of liver enzymes, kidney function, lipids, and blood sugar).

Disease-specific laboratory tests and imaging data were collected for 15 disease groups. For example, we collected information related to surgical history, chemotherapy, hormonal therapy, radiotherapy, and tumor markers for 13 types of cancers. Echocardiogram and coronary angiography information were collected for cardiovascular diseases. Detailed clinical information for each case, such as disease onset, symptoms, subtypes, severity, and complications, was collected separately for disease-specific items. Because the BBJ included both incident and prevalent cases, the duration of disease at registration was calculated based on the date of onset or diagnosis of disease and the date of enrollment. All surveys were performed by medical coordinators at cooperating hospitals.

In this analysis, body mass index (kg/m^2^) was calculated on the basis of the self-reported height and body weight. Hypertension was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or a prescription of antihypertensive drugs.

Data cleansing {#sec2.4}
--------------

To improve the quality of the baseline survey data, we reviewed all data items and performed data cleansing for 4627 out of 17,850 items that were available for \>50% of participants or that were determined to be clinically important variables (e.g., TNM classification for cancer). We checked the distribution of all numeric data and excluded outliers for each variable. For categorical data, we checked the concordance of related variables and excluded discordant data in order to achieve consistency among the values.

Blood sampling and storage {#sec2.5}
--------------------------

A 14 mL sample of whole blood was obtained from each participant at baseline using two 7 mL EDTA-containing tubes. One 7 mL sample of whole blood was sent to one of three commercial laboratories (SRL, BML, and MBC, Japan) for DNA extraction. After DNA was extracted according to the standard procedures in each laboratory, DNA concentration was adjusted to 100 ng/μL and dispensed into three 1 mL tubes with 2D barcodes at the bottom. All DNA tubes were stored at 4--10 °C and delivered to the BBJ. After checking the concordance of the 2D barcodes on the DNA tubes with participant anonymized numbers, all DNA samples were stored in the DNA bank at 4 °C ([Fig. 3](#fig3){ref-type="fig"}). For children or participants with whom there were difficulties in drawing blood, we collected buccal swabs, nail trimmings, or hair trimmings to extract DNA.

Another 7 mL sample of whole blood was centrifuged according to standard procedures at each cooperating hospital, and the resultant serum was dispensed into three 1 mL tubes and labeled with 2D barcodes. All serum samples were initially stored at −80 °C at cooperating hospitals. After several samples were stored, these samples were then delivered to the BBJ. After checking the concordance of the 2D barcodes on the serum tubes with participant anonymized numbers, all serum samples were stored in the serum bank at −150 °C ([Fig. 4](#fig4){ref-type="fig"}). Participants were requested to provide serum samples once a year starting the year following enrollment until March 2013.

Follow-up surveys {#sec2.6}
-----------------

After the baseline survey, we continuously collected clinical information from participants through reviews of medical records once a year until March 2013. If a participant developed a new disease from among the 47 target diseases, medical coordinators registered this new disease and collected relevant clinical information from medical records.

In addition, we collected survival data for participants with any of 32 of the 47 target diseases based on the participants\' registered disease in the 2010 medical record survey. Medical coordinators initially checked the date of last visit and identified participants who had not visited the hospital in more than one year or who had died during the follow-up period. Hospitals requested a copy of the resident card for these participants from local government offices. Medical coordinators then recorded whether the participants were alive, had moved, were unidentified, or had died. For participants who had moved, new addresses were recorded for the next survival survey. For deceased participants, medical coordinators recorded the date of death. We obtained vital statistics from the Statistics and Information Department of the Ministry of Health, Labour and Welfare in Japan and identified the cause of death according to ICD-10 code by matching birth date, date of death, sex, and local government code.

Ethical review {#sec2.7}
--------------

The study protocol for the BBJ Project was approved by the research ethics committees at the Institute of Medical Science, the University of Tokyo, the RIKEN Yokohama Institute, and the 12 cooperating hospitals. All participants gave written consent to participate in the study.

Results {#sec3}
=======

A flow diagram describing the process for the baseline survey and survival survey is shown in [Fig. 5](#fig5){ref-type="fig"}. There were 200,000 patients who were enrolled in the study. Since the clinical information of participants who withdrew informed consent or who were mistakenly enrolled was already removed from the clinical database, baseline data for 199,982 participants were available in this analysis.

Of the 200,000 participants, 161,823 participants were registered with any of 32 diseases during the 2010 medical record survey. Among them, we excluded 20,211 participants who were enrolled at hospitals that withdrew from the BioBank Project, those who refused to complete the follow-up survey, those who withdrew informed consent, or those who were mistakenly enrolled. Finally, survival data for 141,612 participants were available for analysis. The follow-up rate was 97.0%, and the mean follow-up period was 7.7 years. The details of the results of the follow-up survey are described in another report.[@bib9]

The total number of cases was 291,274 at baseline ([Table 2](#tbl2){ref-type="table"}). The largest number of cases was related to dyslipidemia followed by diabetes mellitus. Information on disease onset or diagnosis was collected for 31 diseases. When we evaluated disease duration at registration, the median disease duration was short for most cancer cases, but was long for cases of atopic dermatitis, bronchial asthma, and rheumatoid arthritis, indicating that the proportion of prevalent cases was high for these diseases. Among the participants, 53.1% were male ([Table 3](#tbl3){ref-type="table"}). The average age was 62.7 years for male patients and 61.5 years for female patients. Among participants aged 20 years or older, 27.5% of male and 23.7% of female patients were overweight or obese. The proportion of current smokers was 27.3% for male patients and 10.3% for female patients; the proportion of current drinkers was 54.9% for male patients and 23.6% for female patients. About 51% of male patients and 43% of female patients were defined as having hypertension. Full details regarding baseline characteristics are described in another report.[@bib10]

Discussion {#sec4}
==========

The BBJ Project enrolled approximately 200,000 participants during the first 5-year period of the study. DNA and serum samples stored in the BBJ have enabled investigation of novel genetic factors and new biomarkers related to common diseases. The collected clinical information and follow-up survey data have provided knowledge about the general clinical features of many common diseases in Japan, including both therapeutic conditions and the course of the diseases. Further analyses of the genomic data, clinical information, and follow-up surveys will provide important information regarding the interaction of genetic and clinical factors, and ideally, will eventually contribute to optimized medical treatment that takes into account the individual genetic makeup of the patient.

In recent years, many large-scale biobanks have been established in Europe[@bib11] and the United States,[@bib12] including the UK Biobank,[@bib13] the Auria Biobank,[@bib14] the Estonian Biobank,[@bib15] the Kaiser Biobank,[@bib12] the Million Veteran Program,[@bib16] and the Precision Medicine Initiative Cohort.[@bib17] The UK Biobank has already collected samples from 500,000 participants in the United Kingdom.[@bib13] The Precision Medicine Initiative Cohort plans to collect samples from 1 million participants in the United States.[@bib17] In Japan, the Tohoku Medical Megabank is collecting biological specimens from 150,000 residents.[@bib18] However, most of these biobanks are population-based. Large, patient-based biobanks, such as the BioVU[@bib19] and Mayo Clinic Biobank,[@bib20] are limited. To our knowledge, the BBJ is the first patient-based biobank in the world. This is an advantage in analyzing risk factors of disease prognosis because the BBJ enables examination of data with the longest follow-up period available.

Patient-based biobanks allow for the identification of susceptibility genes for common diseases because large numbers of cases are registered. In contrast, population-based biobanks allow for estimation of environmental exposures and gene--environment interactions, but long-term follow-up is needed because a large number of disease onset cases is needed to achieve sufficient statistical power.[@bib21] Therefore, patient-based biobanks and population-based biobanks should work in cooperation with the goal of implementing personalized, precision medicine in the future.

Conflicts of interest {#sec5}
=====================

The authors declare they have no conflict of interest with respect to this research study and paper.

 {#appsec1}

*Author list for the BioBank Japan Cooperative Hospital Group*.

Members of medical institutions cooperating on the BioBank Japan Project who coauthored this paper include Masaki Shiono, Kazuo Misumi, Reiji Kaieda and Hiromasa Harada (Tokushukai Hospitals); Shiro Minami, Mitsuru Emi and Naoya Emoto (Nippon Medical School); Hiroyuki Daida, Katsumi Miyauchi and Akira Murakami (Juntendo University); Satoshi Asai, Mitsuhiko Moriyama and Yasuo Takahashi (Nihon University); Tomoaki Fujioka and Wataru Obara (Iwate Medical University); Seijiro Mori and Hideki Ito (Tokyo Metropolitan Institute of Gerontology); Satoshi Nagayama and Yoshio Miki (The Cancer Institute Hospital of JFCR); Akihide Masumoto and Akira Yamada (Aso Iizuka Hospital); Yasuko Nishizawa and Ken Kodama (Osaka Medical Center for Cancer and Cardiovascular Diseases); Hiromu Kutsumi and Yoshihisa Sugimoto (Shiga University of Medical Science); Yukihiro Koretsune and Hideo Kusuoka (National Hospital Organization, Osaka National Hospital); and Hideki Yanai (Fukujuji Hospital).

We express our gratitude to all the participants in the BioBank Japan Project. We thank all the medical coordinators of the cooperating hospitals for collecting samples and clinical information, as well as Yasushi Yamashita and staff members of the BioBank Japan Project for administrative support. We also thank Dr. Kumao Toyoshima for his overall supervision of the BioBank Japan Project. This study was supported by funding from the Tailor-Made Medical Treatment with the BBJ Project from Japan Agency for Medical Research and development, AMED (since April 2015), and the Ministry of Education, Culture, Sports, Science and Technology (from April 2003 to March 2015).

Peer review under the responsibility of The Japan Epidemiological Association.

![Geographical distribution of cooperating hospitals.](gr1){#fig1}

![The flow of the collection of the sample.](gr2){#fig2}

![Picture of DNA bank (automated DNA storage system).](gr3){#fig3}

![Picture of serum bank.](gr4){#fig4}

![Flow diagram for baseline and follow-up survey data of study participants.](gr5){#fig5}

###### 

Clinical Information collected during the annual BioBank Japan survey.

Table 1

  Categories                     Classifications
  ------------------------------ --------------------------------
  Common items                   Basic clinical Information
                                 Current drug use
                                 History of adverse drug events
  Laboratory examination items   Malignant tumors
                                 Cerebral diseases
                                 Respiratory diseases
                                 Cardiovascular diseases
                                 Liver diseases
                                 Urologic diseases
                                 Metabolic diseases
                                 Endocrine diseases
                                 Connective tissue diseases
                                 Allergic diseases
                                 Dermatological diseases
                                 Gynecological diseases
                                 Pediatric diseases
                                 Ophthalmologic diseases
                                 Dental diseases
  Disease-specific items         --

###### 

Number of cases of 47 diseases and disease durations at the time of entry in the BioBank Japan Project.

Table 2

  Disease group                Disease name                                                              Number of cases (with serum)   Median disease duration at entry (interquartile range, years)          
  ---------------------------- ------------------------------------------------------------------------- ------------------------------ --------------------------------------------------------------- ------ -------------
  Malignant tumors             Lung cancer                                                               3779                           \(3777\)                                                        0.7    (0.2--2.9)
                               Esophageal cancer                                                         1291                           \(1290\)                                                        0.4    (0.2--2.8)
                               Gastric cancer                                                            6322                           \(6316\)                                                        1.0    (0.2--4.0)
                               Colorectal cancer                                                         6759                           \(6754\)                                                        1.0    (0.2--3.4)
                               Liver cancer                                                              1924                           \(1922\)                                                        1.2    (0.3--3.3)
                               Pancreas cancer                                                           392                            \(392\)                                                         0.4    (0.1--1.5)
                               Gallbladder/Cholangiocarcinoma                                            392                            \(393\)                                                         0.5    (0.2--2.1)
                               Prostate cancer                                                           5066                           \(5065\)                                                        1.0    (0.3--2.8)
                               Breast cancer                                                             6336                           \(6336\)                                                        0.8    (0.2--3.6)
                               Cervical cancer                                                           1218                           \(1218\)                                                        1.8    (0.4--5.3)
                               Uterine cancer                                                            1026                           \(1026\)                                                        1.5    (0.4--4.4)
                               Ovarian cancer                                                            888                            \(888\)                                                         1.8    (0.5--4.9)
                               Hematopoietic tumor                                                       1307                           \(1303\)                                                        2.4    (0.9--5.1)
  Cerebral diseases            Cerebral infarction                                                       16,534                         (16,522)                                                        2.2    (0.4--5.6)
                               Cerebral aneurysm                                                         2710                           \(2709\)                                                        N/A    
                               Epilepsy                                                                  2303                           \(2275\)                                                        5.6    (1.7--13.4)
  Respiratory diseases         Bronchial asthma                                                          8700                           \(8642\)                                                        9.0    (3.0--20.0)
                               Pulmonary tuberculosis                                                    863                            \(862\)                                                         N/A    
                               Chronic obstructive pulmonary disease[a](#tbl2fna){ref-type="table-fn"}   2774                           \(2771\)                                                        3.0    (1.0--8.0)
                               Interstitial lung disease/Pulmonary fibrosis                              808                            \(804\)                                                         3.0    (1.0--7.0)
  Cardiovascular diseases      Myocardial infarction                                                     13,272                         (13,270)                                                        3.8    (0.7--8.7)
                               Unstable angina[a](#tbl2fna){ref-type="table-fn"}                         4330                           \(4324\)                                                        2.6    (0.5--6.4)
                               Stable angina[a](#tbl2fna){ref-type="table-fn"}                           14,807                         (14,800)                                                        3.6    (1.0--7.9)
                               Arrhythmia[a](#tbl2fna){ref-type="table-fn"}                              15,912                         (15,905)                                                        3.7    (1.1--8.3)
                               Heart failure[a](#tbl2fna){ref-type="table-fn"}                           7610                           \(7601\)                                                        1.9    (0.4--5.4)
                               Peripheral arterial diseases                                              2683                           \(2679\)                                                        N/A    
  Liver diseases               Chronic hepatitis B                                                       1346                           \(1345\)                                                        N/A    
                               Chronic hepatitis C                                                       5819                           \(5817\)                                                        N/A    
                               Liver cirrhosis                                                           2519                           \(2509\)                                                        N/A    
  Urologic diseases            Nephrotic syndrome                                                        1056                           \(1007\)                                                        N/A    
                               Urolithiasis                                                              6307                           \(6306\)                                                        N/A    
  Metabolic diseases           Osteoporosis                                                              6743                           \(6739\)                                                        N/A    
                               Diabetes mellitus[b](#tbl2fnb){ref-type="table-fn"}                       39,697                         (39,686)                                                        6.0    (2.0--12.0)
                               Dyslipidemia[b](#tbl2fnb){ref-type="table-fn"}                            43,812                         (43,787)                                                        3.0    (1.0--7.0)
  Endocrine diseases           Graves\' disease                                                          2323                           \(2322\)                                                        N/A    
  Connective tissue diseases   Rheumatoid arthritis                                                      4139                           \(4139\)                                                        7.7    (2.6--15.3)
  Allergic diseases            Hay fever                                                                 5658                           \(5645\)                                                        N/A    
  Dermatologic diseases        Drug eruption                                                             585                            \(586\)                                                         N/A    
                               Atopic dermatitis[a](#tbl2fna){ref-type="table-fn"}                       2938                           \(2896\)                                                        16.0   (5.0--25.0)
                               Keloid                                                                    809                            \(808\)                                                         N/A    
  Gynecologic diseases         Uterine fibroid                                                           5904                           \(5902\)                                                        N/A    
                               Endometriosis                                                             1843                           \(1843\)                                                        N/A    
  Pediatric diseases           Febrile seizure                                                           333                            \(275\)                                                         N/A    
  Ophthalmologic diseases      Glaucoma                                                                  4755                           \(4753\)                                                        3.6    (1.1--8.2)
                               Cataract                                                                  20,002                         (19,988)                                                        1.5    (0.2--5.4)
  Dental diseases              Periodontitis                                                             3898                           \(3896\)                                                        0.1    (0.0--1.7)
  Other                        Amyotrophic lateral sclerosis[a](#tbl2fna){ref-type="table-fn"}           782                            \(771\)                                                         4.0    (2.1--6.9)

Abbreviation: N/A, not available.

The duration of disease was calculated based on the time of disease onset to the time of entry into the registry.

Because we surveyed calendar year of diagnosis for these diseases, the periods from diagnosis were not measured in units of days and months.

###### 

Characteristics of study participants in the BioBank Japan Study.

Table 3

                                                     Male      Female            
  -------------------------------------------------- --------- -------- -------- ------
  Sex                                                106,093   53.1     93,696   46.9
  Age group at entry (years)                                                     
   \<20                                              1413      1.3      982      1.0
   20--29                                            2062      1.9      2842     3.0
   30--39                                            4815      4.5      6534     7.0
   40--49                                            8302      7.8      9483     10.1
   50--59                                            19,515    18.4     16,410   17.5
   60--69                                            31,637    29.8     23,796   25.4
   70--79                                            30,065    28.3     24,106   25.7
   ≥80                                               8272      7.8      9522     10.2
   Unknown                                           12        0.0      21       0.0
  BMI[a](#tbl3fna){ref-type="table-fn"} (kg/m^2^)                                
   Lean (BMI \< 18.5)                                5653      5.4      8525     9.2
   Normal (18.5 ≤ BMI \< 25)                         63,137    60.3     55,330   59.7
   Overweight (25 ≤ BMI \< 30)                       24,865    23.8     17,826   19.2
   Obese (30 ≤ BMI)                                  3898      3.7      4202     4.5
   Unknown                                           7115      6.8      6810     7.3
  Smoking status[a](#tbl3fna){ref-type="table-fn"}                               
   Never smoker                                      25,690    24.5     71,637   77.3
   Ex-smoker                                         44,919    42.9     8521     9.2
   Current smoker                                    28,524    27.3     9505     10.3
   Smoker, unknown current status                    3547      3.4      1293     1.4
   Unknown if ever smoked                            1988      1.9      1737     1.9
  Alcohol intake[a](#tbl3fna){ref-type="table-fn"}                               
   Never drinker                                     30,933    29.6     64,987   70.1
   Ex-drinker                                        13,618    13.0     3614     3.9
   Current drinker (0--10 g/day)                     14,610    14.0     11,818   12.7
   Current drinker (10--20 g/day)                    10,296    9.8      3801     4.1
   Current drinker (20--60 g/day)                    20,884    20.0     3251     3.5
   Current drinker (60 + g/day)                      7496      7.2      765      0.8
   Drinker, unknown current status                   4175      4.0      2277     2.5
   Unknown                                           2656      2.5      2180     2.4
  Hypertension                                                                   
   Normotension                                      37,898    35.7     40,692   43.4
   Hypertension                                      53,962    50.9     38,127   40.7
   Unknown                                           14,233    13.4     14,877   15.9
  Physical exercise                                                              
   Three or more times a week                        21,558    20.3     20,159   21.5
   Once or twice a week                              3692      3.5      6132     6.5
   No habit                                          68,367    64.4     56,796   60.6
   Unknown                                           12,476    11.8     10,609   11.3

Because the sex was unknown, 193 participants were excluded from this analysis.

Abbreviation: BMI, body mass index.

People of unknown age or under the age of 20 were excluded.

[^1]: Hospital Group members are listed in [Appendix A](#appsec1){ref-type="sec"}.
